| Background and Objective:Tet methylcytosine dioxygenase2(TET2) gene mutations have recently been recognized in acute myeloid leukemia (AML). However, the prognostic roles of TET2mutations in AML still remain controversial. In this study, we performed a meta-analysis to evaluate the prognostic significance of TET2mutations in AML.Methods:An electronic literature search of public databases was performed, publications assessing the prognostic significance of TET2mutations in AML were identified up to October2013. A meta-analysis was performed to generate combined hazard ratios (HRs) with95%confidence intervals (CIs) for overall survival (OS) and event-free survival (EFS).Results:Eight studies, covering2,552AML patients, were included in this analysis. Pooled hazard ratios (HRs) indicated that TET2mutations had a poor prognostic impact on the survival of AML patients; the combined HR for overall survival (OS) was1.53and the summary HR for event-free survival (EFS) was1.64. Additionally, TET2mutations appeared to be an adverse prognostic indicator in both cytogenetically normal (CN)-AML patients (HR for OS:1.43and HR for EFS:1.76) and the subgroups of patients with favorable-risk genotypes (HR for EFS:2.35) and intermediate-I-risk genotypes (HR for EFS:1.57), defined according to the criteria of the European Leukemia Net (ELN).Conclusion:Our study indicated that TET2mutations have an adverse impact on prognosis and may help justify risk-adapted therapeutic strategies for AML patients. |
PDF Full Text Request